Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

3M CO (MMM)

As of 2026-11-17 · 11/15 boxes filled from SEC filings and market data

Report price $181.68 (close 2026-11-16); latest close $177.99 (2026-11-20), -2.0% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -28% · upside +14%

The market is pricing a turnaround at a premium: 26.5x TTM net income and 29.9x tax-normalized operating earnings, with P/S of 3.72x against a 2.9x five-year median, while TTM free cash flow is $2.68B and settlement cash is dated. That supports PASS, not a stronger call, because the evidence cuts both ways. The downside is -29.5% to $128.08, the arithmetic being -15.0% earnings at a compressed P/E of 24.95x (today 29.9x). The upside is +12.0% to $203.48, the arithmetic being +12% earnings at today's P/E of 29.9x. There is no base case: fewer than three comparable peers have a usable multiple and the company's own history gives none, so no comparable peer multiple sets one and a base at today's multiple is today's price by construction.

Key numbers

  • Share price: $177.99
  • Market cap: $91.97B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $25.25B
  • EV / EBITDA (TTM): 16.6x
  • P/E (TTM): 26.0x
  • FCF yield: 3.0%
  • Price / book: 22.29x
  • Earnings-quality flags (TTM): none flagged
  • P/E, operating (tax-normalized) (TTM): 29.3x
  • EV / FCF (TTM): 38.2x
  • Revenue growth (latest fiscal year): +1.5%
  • ROIC (TTM): 25.8%
  • WACC: 7.7%
  • Economic profit spread: +18.1 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    3M runs three reportable segments in the FY2025 10-K (Safety and Industrial, Transportation and Electronics, Consumer) versus four in the FY2020 10-K, which still carried Health Care; the Health Care business and drug delivery are no longer part of the reported segments. The revenue base is roughly a third smaller than the FY2021 peak: $35.35B in FY2021 versus $24.95B in FY2025 and $25.25B TTM to 2026-09-30, and FY2023 contains a $10.69B operating loss and $7.00B net loss that make it unusable as an earnings base. Operating income ran $4.82B in FY2024, $4.63B in FY2025 and $4.74B TTM, but operating cash flow ($1.82B FY2024, $2.31B FY2025, $3.63B TTM) sits far below the FY2020-FY2023 range of $5.59B-$8.11B while buybacks ($3.25B FY2025, $3.78B TTM) exceeded operating cash flow in both periods.

  2. ○ 2. Competitive advantage

    The record shows a margin that holds but does not widen: operating margin 22.2% (FY2020), 20.8% (FY2021), 16.7% (FY2022), 19.6% (FY2024), 18.6% (FY2025) and 18.8% (TTM to Sep 2026), while revenue fell from $35.35B in FY2021 to $24.95B in FY2025 — evidence of pricing power and scale, not of growth. Nothing in the sources quantifies brand, market share, switching costs or customer retention, and no competitor is named; the only supports the filings actually point to are patent/intellectual property protection and a global footprint (56% of 2025 revenue outside the U.S., which the 10-K frames as a risk, not an advantage). Counterweights are visible in the numbers: operating cash flow of $2.31B against net income of $3.25B in FY2025, and a $10.5B–$12.5B PFAS settlement payable 2024 through 2036. The advantage is therefore asserted rather than demonstrated, and its economic rent is being consumed by litigation rather than showing up in cash.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 (quarter ended 2026-09-30) was a modest top-line quarter with a big reported-margin and EPS jump that is not all operating: GAAP sales $6,584 million, up 1.0% YoY (organic +0.2%), GAAP operating margin 23.7% and adjusted 26.2%. Reported GAAP EPS of $2.63 (up 70%) leans on a Solventum stake revaluation, while adjusted EPS of $2.50 rose 12% and FY2026 adjusted EPS guidance was raised to $9.10-$9.15. Cash was $5.2 billion at September 30, 2026 versus $5.9 billion at December 31, 2025, after $3.2 billion of buybacks and $1.9 billion for Madison, with nine-month operating cash flow of $2.0 billion. The 10-Q reports no material change in risk factors.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans